Related content

Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer

By Cremolini Chiara   Schirripa Marta   Loupakis Fotios   Falcone Alfredo  

Colorectal Cancer, Vol. 2, Iss. 5, 2013-10 ,pp. : 411-417

Future Medicine

Access to resources Recommend Favorite

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report

By Kawasaki Kenta   Hamamoto Yasuo   Adachi Masayuki   Kanai Takanori   Takaishi Hiromasa  

Oncology Letters, Vol. 11, Iss. 1, 2016-01 ,pp. : 231-233

Spandidos Publications

Access to resources Recommend Favorite

Intermittent therapy in the palliative treatment of metastatic colorectal cancer

By Powell James   Adams Richard  

Colorectal Cancer, Vol. 2, Iss. 3, 2013-06 ,pp. : 219-232

Future Medicine

Access to resources Recommend Favorite

Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer

By Jefford Michael   Zalcberg John  

American Journal of Cancer, Vol. 4, Iss. 1, 2005-01 ,pp. : 15-34

Adis International

Access to resources Recommend Favorite

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study

By  

The Oncologist, Vol. 23, Iss. 1, 2018-01 ,pp. : 7-15

John Wiley & Sons Inc

Access to resources Recommend Favorite